Search results
-
Bet on One Big Idea--or Diversify? (HBR Case Study and Commentary)
Stuart, TobyArticle HBS-R1311M-EStrategyA unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losse...Starting at €8.20
-
Cadbury Schweppes: Capturing Confectionery (D)
Collis, David J.; Stuart, Toby; Smith, TroyCase HBS-708491-EStrategyIn late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the a...Starting at €5.74
-
Bet on One Big Idea--or Diversify (HBR Case Study)
Stuart, TobyArticle HBS-R1311X-EStrategyA unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losse...Starting at €8.20
-
Bet on One Big Idea--or Diversify (Commentary for HBR Case Study)
Stuart, TobyArticle HBS-R1311Z-EStrategyA unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losse...Starting at €8.20
-
Cadbury Schweppes: Capturing Confectionery (A)
Collis, David J.; Stuart, Toby; Smith, TroyCase HBS-708453-EStrategyIn late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the a...Starting at €8.20
-
Cadbury Schweppes: Capturing Confectionery (B)
Collis, David J.; Stuart, Toby; Smith, TroyCase HBS-708454-EStrategyIn late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the a...Starting at €5.74
-
Cadbury Schweppes: Capturing Confectionery (C)
Collis, David J.; Stuart, Toby; Smith, TroyCase HBS-708455-EStrategyIn late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the a...Starting at €5.74